PT - JOURNAL ARTICLE AU - David B. Page AU - Ariel Bulua Bourla AU - Anthony Daniyan AU - Jarushka Naidoo AU - Eric Smith AU - Melody Smith AU - Claire Friedman AU - Danny N. Khalil AU - Samuel Funt AU - Alexander N. Shoushtari AU - Willem W. Overwijk AU - Padmanee Sharma AU - Margaret K. Callahan TI - Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer AID - 10.1186/s40425-015-0072-2 DP - 2015 Dec 01 TA - Journal for ImmunoTherapy of Cancer PG - 25 VI - 3 IP - 1 4099 - http://jitc.bmj.com/content/3/1/25.short 4100 - http://jitc.bmj.com/content/3/1/25.full SO - J Immunother Cancer2015 Dec 01; 3 AB - The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the fundamentals of tumor immunology are translating into clinical success, with recent US Food and Drug Administration approval of several immunotherapies that improve clinical outcomes across prostate cancer, metastatic melanoma, non-small cell lung cancer and lymphocytic leukemia. In tandem with these clinical successes, new technologies such as high-throughput DNA/RNA sequencing, genetic engineering, and streamlined ex vivo cell culturing have paved the way for the next generation of immunotherapies and provided new tools for investigating potential biomarkers of response to existing therapies. During the November 2014 Annual Meeting of the Society of the Immunotherapy of Cancer, leaders in tumor immunology and cancer immunotherapy convened at the second annual SITC Primer to review both current knowledge and future directions in the field. Here, we will review the key discussions across a variety of topics, including innate immunity, adaptive immunity, dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, immune checkpoint blockade, challenges to immunotherapy, monitoring immune responses, and immunotherapy clinical trial design.Abbreviations:ADCAntibody drug conjugateADCCAntibody-dependent cellular cytotoxicityADCPAntibody-dependent cellular phagocytosisALLAcute lymphocytic leukemiaBCRB-cell receptorCARChimeric antigen receptorCDCComplement dependent cytotoxicityCDRComplementarity determining regionCLLChronic lymphocytic leukemiaCTLA4Cytotoxic T-lymphocyte antigen 4DAMPDamage-associated molecular patternDCDendritic cellELISAEnzyme linked immunosorbent assayFabAntigen binding fragmentFcConstant fragmentFDAFood and drug administrationGpGlycoproteinHER2Human epidermal growth factor receptorICOSInducible co-simulatorIFNInterferonILInterleukinLAG3Lymphocyte activation gene 3mAbMonoclonal antibodyMDSCMyeloid derived suppressor cellMHCIMajor histocompatibility complex class IMHCIIMajor histocompatibility complex class IINHLNon-Hodgkin lymphomaNKNatural killer cellPAMPPathogen-associated molecular patternPD-L1Programmed death ligand 1PRRPattern recognition receptorSITCSociety of the immunotherapy of cancerTAATumor associated antigenTAMTumor associated macrophageTCRT-cell receptorT-DM1Trastuzumab emtansineTH1T-helper Type 1 cellTH2T-helper Type 2 cellTILTumor infiltrating lymphocyteTLRToll-like receptorTLSTertiary lymphoid structureVDJVariability, Diversity, and Joining